Oloctinebart Biosimilar – Anti-Mac-2 antigen mAb – Research Grade from ProteoGenix; catalogue PX-TA1960; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Oloctinebart Biosimilar – Anti-Mac-2 antigen mAb – Research Grade: A Promising Antibody for Mac-2 Antigen Targeted Therapy
Oloctinebart Biosimilar – Anti-Mac-2 antigen mAb – Research Grade is a monoclonal antibody (mAb) that has been developed as a biosimilar to the original Oloctinebart mAb. It specifically targets the Mac-2 antigen, a protein that is overexpressed in various types of cancer and inflammatory diseases. This biosimilar has been extensively studied and has shown promising results in preclinical and clinical trials, making it a potential therapeutic option for a wide range of diseases.
Oloctinebart Biosimilar is a recombinant humanized IgG1 mAb, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The variable regions of the heavy and light chains are responsible for the specific binding to the Mac-2 antigen, while the constant regions determine the antibody’s effector functions.
Oloctinebart Biosimilar binds specifically to the Mac-2 antigen, which is a transmembrane glycoprotein that is highly expressed on the surface of cancer cells and activated immune cells. This binding leads to the inhibition of Mac-2 antigen signaling pathways, resulting in the suppression of tumor growth and inflammation. Additionally, Oloctinebart Biosimilar has been shown to induce antibody-dependent cellular cytotoxicity (ADCC), which further enhances its anti-tumor activity.
Oloctinebart Biosimilar has shown promising results in preclinical studies, exhibiting potent anti-tumor activity in various types of cancer, including breast, lung, and colon cancer. It has also demonstrated efficacy in inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. In addition, Oloctinebart Biosimilar has been found to have a favorable safety profile, with no significant adverse effects reported in clinical trials.
Oloctinebart Biosimilar has undergone several clinical trials to evaluate its safety and efficacy. In a phase I study, it was found to be well-tolerated and showed promising anti-tumor activity in patients with advanced solid tumors. A phase II trial in patients with metastatic breast cancer also showed encouraging results, with a significant increase in progression-free survival compared to standard treatment. Currently, Oloctinebart Biosimilar is in phase III trials for various types of cancer and inflammatory diseases.
Oloctinebart Biosimilar – Anti-Mac-2 antigen mAb – Research Grade is a promising antibody that specifically targets the Mac-2 antigen, a protein that is overexpressed in cancer and inflammatory diseases. Its unique mechanism of action and favorable safety profile make it a potential therapeutic option for a wide range of diseases. With ongoing clinical trials, Oloctinebart Biosimilar has the potential to become a valuable treatment option for patients in need.
Antibody, therapeutic target, Mac-2 antigen, biosimilar, monoclonal antibody, cancer, inflammatory diseases, preclinical, clinical trials, safety, efficacy.
ProteoGenix catalogue number PX-TA1960. For research use only.
Target: Oloctinebart Biosimilar – Anti-Mac-2 antigen mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: 0.01M PBS, pH 7.4; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Oloctinebart Biosimilar – Anti-Mac-2 antigen mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
